ABL Diagnostics, a company specialised in molecular diagnostics for infectious diseases, announces that its Board of Directors, at its meeting held on April 30, 2026, has decided to propose to the Combined General Meeting to be held on June 30, 2026, the distribution of a dividend of €0.11 per share for the financial year ended December 31, 2025.
This proposal, which remains subject to shareholders’ approval, is in line with the Company’s dividend policy, following the first dividend paid in respect of FY2024 in the amount of €0.05 per share. It reflects ABL Diagnostics’ intention to establish a sustainable shareholder return, consistent with its development and financial position.
The proposed dividend amounts to approximately €1.77 million in aggregate and would, if approved, be detached on July 3, 2026, with payment scheduled for July 7, 2026, entirely in cash.
This proposal comes in a context of significant improvement in the Company’s financial performance for FY2025. ABL Diagnostics reported revenue of €6.95 million, representing an increase of over 30% compared to the previous year, as well as net profit close to €1.0 million, reflecting strong growth. This performance was accompanied by a significant improvement in operating profitability and strengthened cash generation, allowing for a marked reduction in net debt.
In this context, the proposed dividend distribution reflects ABL Diagnostics’ ability to combine business growth, improved profitability and financial discipline. It also illustrates a balanced approach between funding the investments required to support the Company’s development and sharing value creation with its shareholders.
ABL Diagnostics continues to implement its strategy focused on expanding its molecular diagnostics solutions portfolio, strengthening its international footprint and progressively deploying new integrated activities. In a sector where growth-stage diagnostic companies typically prioritise reinvestment, the Company’s ability to propose an increasing dividend reflects the growing maturity of its business model.
ABL Diagnostics’ dividend policy may evolve over time depending on its results, financial position, investment needs and development opportunities.
This press release contains forward-looking statements based on the Company’s current expectations. These statements involve risks and uncertainties that may cause actual results to differ materially. The payment of the dividend remains subject to approval by the General Meeting of shareholders.
More related news:
Helios Technologies Strengthens Finance and Accounting Leadership Team
WeFi Technology Group: Leading the Transformation in Channel Finance
Kraft Heinz Boosts Canada Production with USD 250M Montreal Investment
